The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ogawa, H.
Right arrow Articles by Binion, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ogawa, H.
Right arrow Articles by Binion, D. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
The Journal of Immunology, 2003, 170: 5956-5964.
Copyright © 2003 by The American Association of Immunologists

Mechanisms of Endotoxin Tolerance in Human Intestinal Microvascular Endothelial Cells 1

Hitoshi Ogawa*, Parvaneh Rafiee{dagger},{ddagger}, Jan Heidemann*, Pamela J. Fisher*, Nathan A. Johnson*, Mary F. Otterson{ddagger},§, Balaraman Kalyanaraman, Kirkwood A. Pritchard, Jr.{dagger},{ddagger} and David G. Binion2,*,§

Divisions of * Gastroenterology and Hepatology and {dagger} Pediatric Surgery, {ddagger} Department of Surgery, § Digestive Disease Center, and Free Radical Research Center, Froedtert Memorial Lutheran Hospital, Milwaukee Veterans Administration Medical Center, Children’s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI 53226


    Abstract
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Lipopolysaccharide (endotoxin) tolerance is well described in monocytes and macrophages, but is less well characterized in endothelial cells. Because intestinal microvascular endothelial cells exhibit a strong immune response to LPS challenge and play a critical regulatory role in gut inflammation, we sought to characterize the activation response of these cells to repeated LPS exposure. Primary cultures of human intestinal microvascular endothelial cells (HIMEC) were stimulated with LPS over 6–60 h and activation was assessed using U937 leukocyte adhesion, expression of E-selectin, ICAM-1, VCAM-1, IL-6, IL-8, manganese superoxide dismutase, HLA-DR, and CD86. Effect of repeat LPS stimulation on HIMEC NF-{kappa}B and mitogen-activated protein kinase (MAPK) activation, generation of superoxide anion, and Toll-like receptor 4 expression was characterized. LPS pretreatment of HIMEC for 24–48 h significantly decreased leukocyte adhesion after subsequent LPS stimulation. LPS pretreatment inhibited expression of E-selectin, VCAM-1, IL-6, and CD86, while ICAM-1, IL-8, and HLA-DR were not altered. Manganese superoxide dismutase expression increased with repeated LPS stimulation, with a reduction in intracellular superoxide. NF-{kappa}B activation was transiently inhibited by LPS pretreatment for 6 h, but not at later time points. In contrast, p44/42 MAPK, p38 MAPK, and c-Jun N-terminal kinase activation demonstrated inhibition by LPS pretreatment 24 or 48 h prior. Toll-like receptor 4 expression on HIMEC was not altered by LPS. HIMEC exhibit endotoxin tolerance after repeat LPS exposure in vitro, characterized by diminished activation and intracellular superoxide anion concentration, and reduced leukocyte adhesion. HIMEC possess specific mechanisms of immunoregulatory hyporesponsiveness to repeated LPS exposure.


    Introduction
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Lipopolysaccharide (endotoxin), a major component of the outer surface of Gram-negative bacteria, is a potent activator of both immune and nonimmune cells. Among nonimmune cells, vascular endothelial cells are known to undergo activation in response to LPS stimulation, with enhanced expression of cell adhesion molecules (CAM)3 and cytokines/chemokines. Endothelial activation by LPS leads to enhanced leukocyte adhesion and tissue recruitment from the circulation, a key regulatory step in the inflammatory response. We have reported that cultured human intestinal microvascular endothelial cells (HIMEC) are also strongly activated by bacterial LPS, as demonstrated by significantly enhanced CAM expression and increased leukocyte-binding activity (1). As described in monocytes and macrophages, endothelial cells are also believed to undergo activation through ligation of Toll-like receptor 4 (TLR4), a recently identified receptor and signal transducer of LPS (2, 3, 4). Ligation of TLR4 leads to recruitment of MyD88, phosphorylation of IL-1R-associated kinase, oligomerization of TNFR-associated factor 6, and subsequent degradation of I-{kappa}B. These events lead to the activation of NF-{kappa}B, and resultant transcription of immune response genes (2).

Although LPS is a potent cellular activator, repeated endotoxin challenge may lead to a temporary insensitivity of cells toward subsequent LPS stimulation. This phenomenon of LPS tolerance has been described in vivo with reduced LPS lethality in mice pretreated with low-dose LPS (5), as well as in vitro with a reduced capacity of monocytes isolated from septic patients to release proinflammatory cytokines in response to further LPS stimulation (6). Furthermore, repeated LPS stimulation of isolated macrophages or monocytes leads to a reduced production of proinflammatory cytokines such as TNF-{alpha} or IL-1{beta} (7, 8). LPS tolerance is considered an adaptive response, which evolves as a protective mechanism to curb the infected host’s continuous response to the invading bacterial organisms, and thereby reduce the autotoxic effect precipitated by overproduction of inflammatory mediators (9, 10).

Because the intestinal mucosal surfaces are in continuous contact with luminal bacteria and their products, it can be expected that the mucosal immune system possesses immunoregulatory mechanisms to avoid an enhanced, destructive inflammatory response toward enteric flora and endotoxin. We hypothesized that microvascular endothelial cells from the human intestine exhibit specific mechanisms for LPS tolerance, given their proximity to the enteric flora and their otherwise strong innate response to LPS. In this study, we demonstrate endotoxin tolerance in primary cultures of HIMEC. HIMEC demonstrate a regulated physiologic response to repeat LPS challenge, mediated in part through inhibition of mitogen-activated protein kinase (MAPK) signaling cascades, altered cytokine and CAM expression, enhanced oxyradical defense via increased expression of manganese superoxide dismutase (Mn-SOD), and diminished intracellular superoxide anion, which result in significantly reduced leukocyte adhesion.


    Materials and Methods
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Isolation and culture of HIMEC

HIMEC isolation was performed, as described previously (1). In brief, surgical specimens obtained from small intestine or colon were rinsed, and mucosal strips were dissected, washed, and digested in a type II collagenase solution (Worthington Biochemical, Freehold, NJ). Microvascular endothelial cells were extruded by mechanical compression and plated onto fibronectin-coated tissue culture dishes in growth medium (MCDB 131 medium; Sigma-Aldrich, St. Louis, MO) containing 20% FBS and endothelial cell growth supplement (Upstate Biotechnology, Lake Placid, NY). After 7–10 days of culture, endothelial cell clusters were physically isolated, and a pure culture was obtained. All experiments were conducted on cultures between passages 8 and 14.

Bacterial LPS

LPS (Escherichia coli 0111:B4; Sigma-Aldrich) was used for both single as well as repeated activation of HIMEC. For the induction of endotoxin tolerance, cultures were treated with 0.5 µg/ml LPS either for 24 h (single pretreatment at 24 h before LPS stimulation) or 48 h (dual pretreatment at 48 and 24 h before LPS stimulation). For the stimulation immediately before assay, cultures were treated with 1 µg/ml LPS.

Endothelial-Leukocyte adhesion assays

For static endothelial-leukocyte adhesion assays, U937 cells (a human monocyte-like cell line) were labeled by incubating with 10 µM 2',7'-bis-(2-carboxyethyl)-5 carboxyfluorescein acetoxymethylester (Molecular Probes, Eugene, OR) for 30 min at 37°C. The labeled U937 cells (1 x 106/well) were added to HIMEC monolayers grown in 24-well tissue culture dishes and cocultured at 37°C for 1 h. After washing with PBS, the firmly adherent U937 cells were lysed by adding a lysis buffer containing 1 mM Tris-Cl (pH 8.0) and 1% (v/v) Triton X-100. The fluorescence intensity of these lysed cells was measured, and the numbers of adherent cells were estimated using a standard curve generated by a serial dilution of known cell numbers. Data from triplicate wells were expressed as a mean of attached U937 cells/well ± SEM.

Endothelial-U937 binding was also assessed using a low shear stress flow adhesion assay, as described previously (11). Briefly, the confluent HIMEC monolayers were placed in a parallel plate flow chamber, and U937 cells (5 x 105/ml) were passed over the endothelial monolayer at 1 dyne/cm2 (flow rate of 0.9 ml/min). A charge-coupled device camera mounted on an Olympus phase contrast microscope (CK2) was used to visualize the flowing leukocytes in the chamber (original magnification, x100), and the adhesion assay was simultaneously captured on a videotape recorder. Tapes were reviewed retrospectively, and adherent numbers of U937 were counted in a minimum of 12 random fields. When indicated, the blocking mAbs for E-selectin, ICAM-1, VCAM-1, or isotype control IgG (30 µg/ml; R&D Systems, Minneapolis, MN) were added to culture medium 1 h before assay. Data were expressed as the mean number of adherent U937 cells/mm2 of endothelial cell surface ± SEM.

RNA preparation and semiquantitative RT-PCR

Total RNA was extracted from HIMEC using TRIzol (Life Technologies, Rockville, MD) and treated with DNase I, amplification grade (Life Technologies), according to the manufacturer’s instruction. The cDNA was generated from 1 µg of total RNA with oligo(dT) primer using Superscript First-Strand Synthesis System for RT-PCR (Life Technologies), according to the protocol, and filled up to 80 µl. A total of 4 µl of cDNA solution was used for RT-PCR in a total volume of 40 µl containing 0.5 µM of sense and antisense primers. The specific primers, the size of PCR products, and the number of PCR amplification cycles for each assay are shown in Table I. PCR amplifications were performed at 94°C for 1 min, 60°C for 1 min, 72°C for 1 min, and followed by final extension for 7 min. A total of 20 µl of PCR product was visualized on 1% agarose gels stained with ethidium bromide.


View this table:
[in this window]
[in a new window]
 
Table I. Specific primers and conditions for semiquantitative RT-PCR

 
Assessment of E-selectin, ICAM-1, and VCAM-1 surface expression on HIMEC

HIMEC surface expression of E-selectin, ICAM-1, and VCAM-1 was examined using a RIA, as described previously (1). Briefly, monolayers were incubated with mouse anti-human E-selectin, ICAM-1, or VCAM-1 mAbs (R&D Systems) for 60 min at 4°C, rinsed, then incubated with goat anti-mouse biotinylated Fab' fragment (Jackson ImmunoResearch Laboratories, West Grove, PA) for 60 min at 4°C. After washing, 125I-labeled streptavidin (5 µCi/ml) (Amersham Bioscience, Piscataway, NJ) was applied to wells to detect adherent secondary Ab. After unbound radioactivity was washed off, cells were lysed with 1.0% (v/v) Triton X-100 in medium, and radioactivity was quantified in a gamma counter. Data from triplicate wells were expressed as a mean of 125I-labeled streptavidin bound (cpm/well) ± SEM.

Measurement of IL-6 and IL-8 in HIMEC culture supernatant by ELISA

IL-6 or IL-8 concentrations in conditioned medium were measured using commercially available ELISA kits (R&D Systems), according to the manufacturer’s protocol. Experiments were conducted in triplicate, and results are shown as mean picograms per milliliter ± SEM.

SDS-PAGE and Western blotting

For Mn-SOD protein expression, cells were lysed in buffer containing 20 mM HEPES, 150 mM NaCl, 1% (v/v) Nonidet P-40, 0.1% (w/v) SDS, 1 mM EDTA, and 0.5% (v/v) protease inhibitor cocktail (protease inhibitor cocktail III; Calbiochem, San Diego, CA), and incubated on ice for 60 min. Lysates were centrifuged for 10 min at 10,000 x g, and resulting supernatants were used. A total of 10 µg of protein per lane was separated by SDS-PAGE, and transferred onto nitrocellulose membranes. After blocking in PBS containing 2% (w/v) BSA and 3% (w/v) nonfat dry milk, blots were washed three times in TBST (10 mM Tris-Cl, 150 mM NaCl, 0.1% (v/v) Tween 20, pH 7.4) and probed overnight at 4°C with anti-Mn-SOD polyclonal Ab (Upstate Biotechnology). Following three washes in TBST, membranes were incubated for 1 h at room temperature with secondary HRP-conjugated anti-rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA). Bands were detected using ECL reagents (Amersham Bioscience).

For the detection of MAPK activation, cells were lysed in buffer containing 10 mM sodium orthovanadate (pH 10), 40 mM {beta}-glycerol phosphate, and 20 mM sodium fluoride, and incubated on ice for 30 min. A total of 15 µg of protein per lane was separated by SDS-PAGE, and Western blotting was performed, as described above, using anti-total or phospho- p44/42, or p38 MAPK, or stress-activated protein kinase/c-Jun N-terminal kinase (JNK) polyclonal Ab (Cell Signaling Technology, Beverly, MA).

Western blotting for TLR4 protein expression in HIMEC was performed using cell membrane-enriched protein fractions (12). Briefly, cells were washed and homogenized in lysis buffer containing 50 mM Tris-HCl buffer (pH 7.4), protease inhibitor cocktail, and 1 mM EDTA. The homogenate was centrifuged at 1000 rpm for 10 min. The supernatant was collected and centrifuged at 48,000 x g for 30 min. The resulting pellet (membrane protein-enriched fraction) was resuspended in lysis buffer, and 20 µg of membrane protein per lane was separated by SDS-PAGE. Western blotting was performed, as described above, using anti-TLR4 polyclonal Ab (H80; Santa Cruz Biotechnology).

Assessment of intracellular superoxide production

HIMEC were grown to confluence in 24-well tissue culture dishes. After stimulation with LPS for 2 h with or without LPS pretreatment, hydroethidine (Polysciences, Warrington, PA) was added to culture medium (final concentration = 10 µM) and incubated another 30 min. The cells were washed twice with PBS, and observed under a fluorescence microscope (excitation at 488 nm, emission at 610 nm). In the presence of intracellular superoxide, hydroethidine is converted to ethidine and detected as bright nuclear staining.

EMSA for NF-{kappa}B translocation

Nuclear protein extracts were prepared from HIMEC monolayer, as described previously (13). For the DNA-binding assay, a double-stranded NF-{kappa}B oligonucleotide (5'-AGTTGAGGGGACTTTCCCAGGC-3'; Promega, Madison, WI) was end labeled with [{gamma}-32P]ATP (3000 Ci/mmol at 10 mCi/ml; Amersham Bioscience). Binding reactions (20 µl vol) consisted of 3 µg poly(dI:dC) (Amersham Bioscience), 3 µg nuclear protein extract, and 35 fmol of oligonucleotide, and were incubated at room temperature for 30 min. Reaction products were separated through a 4% polyacrylamide/Tris borate EDTA gel, transferred to Whatman paper, dried, and autoradiographed at -80°C.

Inhibition of p44/42 MAPK, p38 MAPK, JNK, and NF-{kappa}B during HIMEC activation

To examine whether intracellular signaling through p44/42 MAPK, p38 MAPK, JNK, or NF-{kappa}B is involved in HIMEC activation by LPS, HIMEC were incubated in culture medium containing specific inhibitors of p44/42 MAPK (PD98059, 10 µM; Calbiochem), p38 MAPK (SB203580, 5 µM; Calbiochem), JNK (SP600125, 10 µM; Biomol Research Laboratories, Plymouth Meeting, PA), or NF-{kappa}B (Bay11, 2.5 µM; Biomol Research Laboratories) for 2 h before LPS stimulation. After 6-h stimulation with LPS (1 µg/ml), U937 static adhesion and IL-6 secretion were assessed, as described above.

Real-time quantitative RT-PCR (TaqMan) for TLR4 mRNA expression

TLR4 mRNA expression after LPS treatment was assessed by real-time quantitative RT-PCR. The sequences of primers and TaqMan probe used for the quantification of TLR4 mRNA were 5'-TTTATGAAGGTTTCCATAAAAGC-3', 5'-AACTGCCAGGTCTGAGCAATCT-3', and 5'-TET TTGTTGTGGTGTCCCAGCACTTCATCC-TAMRA-3', respectively. The primers and probe for GAPDH used as an internal control were 5'- GAAG GTGAAGGTCGGAGTC-3', 5'-GAAGATGTTGATGGGATT-3', and 5'-FAM-CAAGCTTCCCGTTCTCAGCC-TAMRA-3'. After extraction and DNase I treatment, total RNA underwent reverse transcription and amplification using the TaqMan EZ RT-PCR kit (PE Applied Biosystems, Foster City, CA). The RT-PCR mixture (50 µl) contained 1x TaqMan EZ buffer, 300 nM deoxynucleoside triphosphate (A, G, C, and U), 3 mM manganese acetate, 0.01 U/µl AmpErase uracil N-glycosylase, 0.1 U/µl rTth DNA polymerase, 100 nM TaqMan probe, 200 nM of primers (all from PE Applied Biosystems), and 50 ng total RNA. The RT-PCR was performed in a 96-well optical tray using the ABI PRISM 7700 sequence Detection System (PE Applied Biosystems). TLR4 mRNA and GAPDH mRNA were reverse transcribed at 60°C for 30 min, followed by a PCR cycle with a melting step for 20 s at 94°C and annealing and extension steps for 1 min at 60°C for a total of 40 cycles. All reactions were performed in triplicate. The standard curve was constructed with 4-fold serial dilutions of total RNA from unstimulated HIMEC and composed of 4 points (200, 50, 12.5, and 3.125 ng of total RNA, respectively). The TLR4 and GAPDH relative messages in LPS-stimulated HIMEC compared with unstimulated HIMEC were quantified by measuring parameter threshold cycles (Ct) and by using a standard curve. Data were expressed as TLR4 mRNA/GAPDH mRNA in each of the LPS-treated samples compared with unstimulated HIMEC. Data from triplicate wells were expressed as mean ± SD.


    Results
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Repeated endotoxin stimulation inhibits HIMEC-leukocyte adhesion

As reported previously (1), LPS stimulation resulted in increased numbers of U937 cells binding to the HIMEC monolayer under both static and physiologic flow conditions. When HIMEC monolayers were exposed to repeat LPS activation and assessed using both static and flow conditions, HIMEC-U937 adhesion enhanced by LPS stimulation was significantly decreased by endotoxin pretreatment for 24 and 48 h before assay (Fig. 1, A and B).



View larger version (22K):
[in this window]
[in a new window]
 
FIGURE 1. Effect of LPS pretreatment on HIMEC-U937 adhesion under static or flow conditions. A, Results from a HIMEC-U937 static adhesion assay. HIMEC monolayers were assessed unstimulated (basal adhesion) and following stimulation with LPS (1 µg/ml) for 6 h. Designated cultures were subjected to LPS pretreatment (0.5 µg/ml) for 24 or 48 h before assay. HIMEC display endotoxin tolerance, as LPS pretreatment at 24 and 48 h before assay significantly decreased leukocyte binding. Representative results of an individual static adhesion assay performed on a unique HIMEC culture after repeat LPS stimulation, of a total of three independent experiments. Data from triplicate wells were expressed as the average number of adherent U937 cells/well ± SEM. *, p < 0.05 compared with LPS stimulation without LPS pretreatment using ANOVA. B, HIMEC-U937 adhesion assay under low-shear stress physiologic flow. HIMEC monolayers grown in 35-mm culture dishes were treated, as described above. HIMEC again demonstrate endotoxin tolerance, as LPS pretreatment for 24 or 48 h resulted in significantly decreased leukocyte adhesion following LPS rechallenge. Representative figure from a unique HIMEC culture. Total of three independent experiments was performed. Data are expressed as the average number of adherent U937 cells/mm2 of endothelial cell surface ± SEM. *, p < 0.05 compared with LPS stimulation without LPS pretreatment using ANOVA.

 
Effect of repeated endotoxin stimulation on HIMEC gene expression

LPS stimulation is known to induce endothelial activation, which is characterized by alterations in gene expression and phenotype. Our next series of experiments were performed to characterize alterations in gene expression in HIMEC exposed to repeated LPS stimulation using semiquantitative RT-PCR (Fig. 2).



View larger version (44K):
[in this window]
[in a new window]
 
FIGURE 2. Effect of repeat LPS stimulation on HIMEC gene expression. Semiquantitative RT-PCR for E-selectin, ICAM-1, VCAM-1, IL-6, IL-8, Mn-SOD, HLA-DR{alpha}, and CD86 mRNA expression in HIMEC after repeated LPS stimulation. HIMEC were stimulated with LPS (1 µg/ml) with or without pretreatment with LPS (0.5 µg/ml) for 24 or 48 h, as indicated in the figure. After stimulation, total RNA was extracted and subjected to semiquantitative RT-PCR to assess mRNA expression. To verify that these bands were amplified from cDNA and not from genomic DNA, samples without reverse transcription were used for each PCR and shown in the last lane. E-selectin, IL-6, and CD86 mRNA expression significantly increased following initial LPS activation, but was attenuated by endotoxin pretreatment 24 and 48 h prior. ICAM-1 and IL-8 mRNA were also up-regulated by initial LPS stimulation, and were not affected by prior LPS exposure. VCAM-1 expression decreased following 48-h LPS pretreatment. Mn-SOD and HLA-DR{alpha} mRNA were enhanced by LPS, and remained at high levels despite LPS pretreatment. {beta}-actin served as an internal control. These data indicate that specific genes are either increased or diminished following repeated rounds of endotoxin exposure. Representative gels depicting HIMEC gene expression are shown, of three total independent experiments.

 
E-selectin significantly increased following initial LPS activation, but was attenuated by endotoxin pretreatment 24 and 48 h prior. In marked contrast, ICAM-1 mRNA expression remained elevated despite LPS pretreatment. VCAM-1 mRNA expression was not attenuated by 24-h LPS pretreatment, but did decrease following 48-h LPS exposure in HIMEC.

Both IL-6 and IL-8 mRNA were up-regulated by initial LPS stimulation. However, the magnitude of IL-6 mRNA induction was attenuated by LPS pretreatment, while increases in IL-8 expression were not affected by prior LPS exposure.

Enzymatic oxyradical defense has been described in endothelial cells and plays an essential role in the down-regulation of activation, as increased intracellular levels of superoxide anion mediate endothelial activation (14). Mn-SOD mRNA was strongly enhanced by LPS, and remained at high levels despite LPS pretreatment.

Endothelial cells are believed to function as nonprofessional APCs (15), and we also examined the effect of sustained LPS activation on expression of established (HLA-DR{alpha}) and novel costimulatory molecules (CD86) in HIMEC. HLA-DR{alpha} mRNA was induced by LPS stimulation, and the increased expression was not altered by prior LPS exposure. CD86 was also induced by initial LPS stimulation in HIMEC. However, in contrast to HLA-DR, CD86 mRNA induction was significantly attenuated by LPS pretreatment.

Taken together, these data suggest that a differential response to LPS challenge following endotoxin pretreatment is seen in HIMEC, in which specific genes are either increased or diminished following repeated rounds of endotoxin exposure. These data also suggest that the decreased inflammatory function demonstrated in HIMEC exposed to repeated LPS did not represent exhausted cells, but instead, was a physiologic result of modulated gene expression.

Effect of repeated endotoxin stimulation on HIMEC CAM surface expression

LPS stimulation of HIMEC induced a significant increase in E-selectin exposure at 6 h. LPS pretreatment of HIMEC for 24 or 48 h significantly inhibited the E-selectin expression following LPS stimulation (Fig. 3A). In contrast, ICAM-1 expression in HIMEC after LPS stimulation was not significantly altered by LPS pretreatment (Fig. 3B). VCAM-1 surface expression was significantly inhibited by LPS pretreatment for 48 h (Fig. 3C). These data confirm that the alterations in gene expression seen at the mRNA level are also demonstrated in protein expression in HIMEC undergoing repeated exposure to LPS. Finally, experiments were performed to confirm that these CAM were involved in the adhesion of U937 leukocytes to HIMEC under flow conditions. Anti-E selectin and VCAM-1 mAbs significantly inhibited U937 binding to LPS-stimulated HIMEC (Fig. 3D).



View larger version (31K):
[in this window]
[in a new window]
 
FIGURE 3. Effect of repeat LPS stimulation on HIMEC CAM expression. E-selectin and ICAM-1 surface expression on HIMEC were assessed using a whole cell RIA. Confluent HIMEC monolayers were treated with LPS, as indicated in the figure, before CAM surface detection using anti E-selectin or ICAM-1 mAbs, biotinylated secondary Ab, and 125I-labeled streptavidin before lysis and quantification in a gamma counter. A, HIMEC E-selectin expression induced by LPS stimulation was significantly attenuated by endotoxin pretreatment. B, ICAM-1 surface expression was also enhanced by LPS stimulation, but the expression level was not significantly altered by prior LPS stimulation. C, VCAM-1 expression was attenuated by 48-h pretreatment with LPS. D, Blocking Abs against E-selectin or VCAM-1 inhibit U937 monocyte adhesion to LPS-activated HIMEC under physiologic flow. Assays were done in triplicate, and the data are shown as a mean of the radioactivity of each condition ± SEM. Representative figure from a total of three independent experiments. *, p < 0.05 compared with LPS stimulation without LPS pretreatment using ANOVA.

 
Effect of repeated endotoxin stimulation on cytokine secretion by HIMEC

Both IL-6 and IL-8 secretion from cultured HIMEC monolayers was increased in response to initial LPS stimulation for 6 h. LPS pretreatment significantly diminished the IL-6 secretion by subsequent LPS challenge (Fig. 4A), while IL-8 secretion was not significantly altered (Fig. 4B). Repeated LPS exposure did not completely inhibit the ability of HIMEC to generate IL-6, suggesting that these cells were still able to mount an inflammatory response in the face of prolonged endotoxin exposure.



View larger version (21K):
[in this window]
[in a new window]
 
FIGURE 4. Effect of repeat endotoxin stimulation on cytokine and chemokine production by HIMEC. Assessment of basal and LPS-stimulated IL-6 and IL-8 secretion by HIMEC monolayers using ELISA. HIMEC were treated with LPS, as indicated in the figure, and IL-6 or IL-8 concentrations in culture supernatants were quantified using ELISA. Both IL-6 and IL-8 secretion by HIMEC were enhanced by initial LPS stimulation. However, IL-6 secretion following LPS stimulation was significantly attenuated by endotoxin pretreatment (A), while IL-8 production by HIMEC was not affected (B). Representative data from three individual experiments. *, p < 0.05 compared with LPS stimulation without LPS pretreatment using ANOVA.

 
Repeated endotoxin stimulation enhances HIMEC oxyradical defense

Previous work in endothelial cells has demonstrated that the generation of superoxide anion is integrally linked to activation (14). One of the essential enzymatic intracellular mechanisms for quenching superoxide anion is Mn-SOD. We examined the protein expression of Mn-SOD in HIMEC following repeated exposure to LPS. Mn-SOD protein expression was enhanced by LPS stimulation at 6 h. In marked contrast to the effects seen in CAM, IL-6, and IL-8 production, repeat LPS treatment resulted in a significant increase in Mn-SOD protein expression throughout the evaluation period (Fig. 5A). This data implied that enhanced oxyradical enzymatic defense was a feature of repeated LPS exposure in HIMEC. Unlike the other molecules investigated, the rise in Mn-SOD protein detected in HIMEC cultures repeatedly stimulated with LPS suggests that this enzyme accumulates during chronic endotoxin activation, resulting in a progressive rise in protein, higher than the increase in mRNA that appeared to plateau during the evaluation period.



View larger version (99K):
[in this window]
[in a new window]
 
FIGURE 5. Repeat endotoxin stimulation enhances HIMEC oxyradical defense. A, Western blotting for Mn-SOD expression in HIMEC during repeated LPS treatment. HIMEC were treated with LPS, as indicated in the figure, and Mn-SOD protein in total cell lysates was analyzed by Western blot analysis. Unstimulated HIMEC expressed detectable amounts of Mn-SOD. Mn-SOD expression was markedly increased by 24- and 48-h LPS pretreatment. Representative gel from three independent experiments. B–E, Intracellular superoxide levels in HIMEC are modulated by repeat LPS stimulation. HIMEC monolayer was stimulated with LPS (1 µg/ml) for 2 h after pretreatment with LPS (0.5 µg/ml) for 24 (D) and 48 (E) h before assay. After stimulation, endothelial monolayers were incubated with hydroethidine and observed using a fluorescence microscope. In the presence of intracellular superoxide, hydroethidine is converted to ethidium bromide and detected as bright nuclear staining. B, Unstimulated HIMEC monolayer demonstrates minimal fluorescence with hydroethidine. C, Following LPS stimulation (1 µg/ml) for 2 h, HIMEC loaded with hydroethidine demonstrate a marked increase in nuclear fluorescence staining pattern and intensity. D and E, LPS pretreatment of HIMEC markedly diminishes subsequent increase in superoxide generation and hydroethidine-induced fluorescence. Representative image from triplicate experiments is shown.

 
Repeated endotoxin stimulation diminishes intracellular superoxide generation during subsequent HIMEC activation

We examined the functional sequelae of increased Mn-SOD expression in LPS-activated HIMEC using hydroethidine, an intravital dye used for the detection of superoxide and fluorescence microscopy of live HIMEC monolayers. Hydroethidine passes freely into live cells, and will react rapidly with superoxide anion, resulting in the generation of ethidine, which binds nuclear DNA, generating a nuclear pattern of fluorescence. Unstimulated HIMEC displayed low overall fluorescence intensity when examined using hydroethidine treatment (Fig. 5B). LPS stimulation of HIMEC resulted in bright nuclear staining in a large proportion of cells (Fig. 5C), indicating the generation of superoxide after initial exposure to endotoxin. However, in marked contrast, fluorescence intensity was significantly diminished in the LPS-pretreated HIMEC (Fig. 5, D and E). Using NIH Image analysis software, fluorescence intensity returned to baseline in the LPS-pretreated HIMEC at both 24 and 48 h (data not shown). These data suggest that the mechanism of LPS tolerance in HIMEC involves blunting of intracellular superoxide generation during activation, potentially through the action of increased intracellular Mn-SOD.

Early, but not sustained, inhibition of NF-{kappa}B activation by subsequent LPS stimulation

HIMEC NF-{kappa}B nuclear translocation was detectable at 1 and 2 h after LPS stimulation (1 µg/ml). LPS pretreatment (0.5 µg/ml) for 6 h abolished the NF-{kappa}B activation by the subsequent LPS stimulation (Fig. 6A). However, pretreatment of HIMEC with LPS for 24 or 48 h failed to block NF-{kappa}B activation (Fig. 6B). These data suggest that the inhibition of NF-{kappa}B in LPS-pretreated HIMEC played a transient early role in LPS tolerance that did not appear to persist after 24–48 h.



View larger version (46K):
[in this window]
[in a new window]
 
FIGURE 6. Effect of repeat LPS treatment on NF-{kappa}B activation in HIMEC. HIMEC monolayers were treated with LPS, as indicated in the figure, and NF-{kappa}B translocation was assessed by gel EMSA. A, NF-{kappa}B translocation was observed at 1 or 2 h after initial LPS stimulation, but LPS pretreatment for 6 h inhibited the NF-{kappa}B activation by subsequent LPS stimulation. B, LPS pretreatment for 24 or 48 h failed to block NF-{kappa}B activation. Representative image from one of three independent experiments.

 
Effect of endotoxin and LPS pretreatment on MAPK activation in HIMEC

Phosphorylation of p44/42 MAPK, p38 MAPK, and JNK was detected at 30 min after initial LPS stimulation. However, LPS pretreatment for 24 or 48 h exerted an inhibitory effect on MAPK activation by subsequent LPS stimulation (Fig. 7, A–C). Pretreatment with LPS for 6 h also exerted an inhibitory effect on phosphorylation of MAPK (data not shown). These data, in combination with the previous EMSA experiments, suggest that the hyporesponsiveness induced by repeated LPS challenge in HIMEC may involve multiple pathways at different time points, which include an early, transient NF-{kappa}B inhibition as well as sustained alterations in MAPK signaling.



View larger version (69K):
[in this window]
[in a new window]
 
FIGURE 7. Effect of repeat LPS stimulation on MAPK activation in HIMEC. Western blotting was used to assess the phosphorylation of specific MAPK family members during repeat LPS-induced activation of HIMEC, including: A, p 44/42 MAPK; B, p 38 MAPK; and C, JNK/stress-activated protein kinase. HIMEC were treated with LPS, as indicated in the figure, and phospho-p44/42 MAPK, phospho-p38, and phospho-JNK were detected and compared with total p44/42 MAPK, p38 MAPK, and JNK. Phosphorylation of MAPK family members was observed at 30 min after initial LPS stimulation. LPS pretreatment for 24 or 48 h inhibited the phosphorylation by the subsequent LPS stimulation for all MAPK family members. Representative gels from a total of three independent experiments are shown.

 
The transcription factor NF-{kappa}B and MAPK signaling pathways are involved in the proinflammatory activation of HIMEC by LPS

Next, we examined the contribution of NF-{kappa}B and the MAPK signaling cascades in the LPS-induced activation of HIMEC, focusing on the mechanisms underlying increased leukocyte adhesion and IL-6 secretion. The increased adhesion of U937 cells to HIMEC monolayers by LPS was attenuated by pretreatment with the selective p44/42 inhibitor PD98059, as well as the NF-{kappa}B inhibitor Bay11, but not the selective p38 MAPK inhibitor SB203580 nor the JNK inhibitor SP600125. IL-6 secretion was inhibited by all the MAPK inhibitors, as well as the NF-{kappa}B inhibitor Bay11 (Fig. 8). Previous work in our laboratory has demonstrated that MAPK and NF-{kappa}B activation play a major role in the expression of CAM in HIMEC (16, 17), which is in concert with published data on the role of these activation pathways in the expression of CAM in HUVEC (18). These data also demonstrate that HIMEC activation in response to LPS is mediated through a complex network of signaling events involving NF-{kappa}B as well as MAPK signaling cascades.



View larger version (28K):
[in this window]
[in a new window]
 
FIGURE 8. The effect of MAPK or NF-{kappa}B inhibitors on HIMEC activation. HIMEC monolayers were pretreated with PD98059 (p44/42 MAPK inhibitor), SB203580 (p38 MAPK inhibitor), SP600125 (JNK inhibitor), or Bay11 (NF-{kappa}B inhibitor) for 2 h before LPS stimulation. HIMEC were stimulated with LPS (1 µg/ml) for 6 h, and HIMEC-U937 static adhesion and IL-6 secretion were assessed. A, LPS-induced HIMEC-U937 adhesion was significantly inhibited by SB203580 and Bay11. B, HIMEC IL-6 secretion in response to LPS was significantly diminished by all inhibitors used in this study. These data demonstrate that HIMEC activation in response to LPS is mediated through a complex network of signaling events involving NF-{kappa}B as well as MAPK signaling cascades. Representative data from one of a total of three independent experiments. *, p < 0.05 compared with LPS-stimulated HIMEC cultures by ANOVA.

 
LPS pretreatment does not alter TLR4 expression in HIMEC

Repeated LPS exposure has been shown to alter the levels of TLR4 in murine peritoneal macrophages, and this decreased receptor expression may be a mechanism underlying endotoxin tolerance in specific cell types (19). We performed a series of experiments to determine the mechanism of activation via LPS in HIMEC, and whether alterations in TLR4 expression might accompany endotoxin tolerance in these cells.

To characterize the mechanism of LPS activation in HIMEC, we initially focused experiments on their expression of CD14, a protein that binds LPS, and facilitates signaling through TLR4. As previously described, the majority of endothelial cell lines will fail to express CD14 in vitro, and CD14 was not detected on HIMEC using both cell surface expression RIAs and FACS analysis (data not shown). We performed confirmatory experiments to demonstrate that exogenous, soluble CD14, which is present in culture medium containing FBS, would play a role in LPS-mediated activation of HIMEC. In HIMEC deprived of serum, LPS failed to induce activation of p38 MAPK and p44/42 MAPK (data not shown), demonstrating a need for a serum-derived product in LPS signaling, presumably CD14.

Our next series of experiments were performed to demonstrate the expression of TLR4 in HIMEC. We examined the effect of LPS stimulation on TLR4 mRNA expression at 0, 3, 6, and 24 h after LPS induction, using real-time quantitative RT-PCR. Following LPS treatment (0.5 µg/ml), TLR4 mRNA levels were not changed at any of the time points examined following LPS stimulation (Fig. 9A). Constitutive and LPS-stimulated expression of TLR4 remained unaltered in HIMEC when examined at the protein level. Western blotting of membrane-enriched fractions of unstimulated as well as LPS-pretreated HIMEC demonstrated no alteration in protein levels, suggesting that no receptor internalization of TLR4 had occurred (Fig. 9B). These data suggest that TLR4 is present in HIMEC, but expression of this LPS receptor does not undergo modulation in response to LPS-induced activation, and receptor density at the cell surface will not mediate the altered signaling that accompanies endotoxin tolerance in this microvascular cell population.



View larger version (19K):
[in this window]
[in a new window]
 
FIGURE 9. TLR4 expression in HIMEC is not affected by LPS treatment. A, HIMEC monolayers were treated with LPS for 0, 3, 6, or 24 h, and TLR4 mRNA expression was determined by real-time quantitative RT-PCR. The relative amount of TLR4 mRNA was expressed as TLR4 mRNA/GAPDH mRNA in each of the LPS-treated samples compared with unstimulated HIMEC. Data from triplicate wells are expressed as mean ± SD. Graph shows representative data from a single experiment, repeated in three independent cell lines. These data demonstrate that LPS treatment did not alter TLR4 mRNA expression. B, TLR4 protein expression in LPS-treated HIMEC cultures detected with Western blotting. Membrane protein-enriched fractions were extracted from HIMEC after 0, 6, and 24 h of LPS treatment (0.5 µg/ml), and TLR4 protein expression was examined by Western blotting. These data demonstrate that LPS treatment did not alter TLR4 protein expression, and also indicate that no receptor internalization was apparent in membrane-enriched protein fractions. Representative gel from two independent experiments.

 

    Discussion
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
The innate immune response to LPS is a critical mechanism for host defense, which will induce potent inflammatory activation. However, sustained inflammatory activation in response to LPS may also lead to damaging effects, and is believed to play a major etiopathogenic role in endotoxic shock, multisystem organ failure, and inflammatory bowel disease (20, 21). In the present study, we have characterized immunoregulatory mechanisms involved in endotoxin tolerance in human gut microvascular endothelial cells. Defining mechanisms of immunoregulation in response to LPS in human gut-specific cell populations represents an essential component in our ability to understand mucosal immune homeostasis. Our report is the first description of endotoxin tolerance in human microvascular endothelial cells from the gut, an area of the body that physiologically coexists with high levels of bacterial products, including endotoxin.

Endotoxin tolerance, the LPS-induced transient impaired inflammatory response to subsequent LPS challenge, has been described at the cellular and molecular level most extensively in monocytes and macrophages. Monocytes/macrophages rendered endotoxin tolerant are characterized by: 1) impaired activation of intracellular signaling pathways, including NF-{kappa}B and MAPKs (19); 2) decreased proinflammatory gene transcription and protein production, including TNF-{alpha}, IL-1{beta}, IL-6, and IFN-{gamma} (10); and 3) down-regulated proinflammatory cellular function, including Ag presentation (22). At the present time, there is limited information regarding whether cell types other than monocytes or macrophages display LPS tolerance, especially cells originating from the intestinal mucosa whose surface is in continuous proximity to large amounts of endotoxin. A recent report has shown that HUVECs develop LPS tolerance after repeated LPS challenge, demonstrating reduced polymorphonuclear leukocyte adhesion, E-selectin expression, and NF-{kappa}B mobilization (23). However, because HIMEC are the resident gut microvascular population possessing unique phenotypic, functional, and physiologic properties distinct from HUVEC (1), we conducted the present study to characterize LPS tolerance in this population.

The most important physiologic finding in our investigation was the demonstration of significantly decreased leukocyte binding in HIMEC undergoing prolonged, repeated activation in response to LPS. The binding of circulating leukocytes to the microvascular endothelium is the initial event in leukocyte emigration and extravasation, and is an early and rate-limiting step in tissue inflammation. Thus, the attenuated binding activity in HIMEC after repeated LPS exposure may represent an important down-regulatory mechanism to prevent excessive inflammation in response to chronic LPS exposure. Simultaneously, the phenomenon of altered HIMEC activation in response to repeat LPS stimulation was selective, as altered E-selectin, VCAM-1, and IL-6 expression, but not ICAM-1 or IL-8, were characterized in our study. The attenuated E-selectin expression after repeated LPS challenge was also reported in HUVEC (23), as well as in mouse gut endothelial cells in vivo (24). These results suggest that this down-regulation of E-selectin expression after repeated LPS stimulation may not be specific to mucosal endothelial cells, and more importantly, is observed both in vitro and in vivo.

At present, it is uncertain what molecular mechanisms regulate the patterns of differential gene expression in HIMEC undergoing sustained activation in response to LPS. Our examination of mRNA expression suggests that regulation is occurring at the level of transcription and/or mRNA stability. Our investigation of signaling pathways in HIMEC suggests that modulation of NF-{kappa}B as well as p44/42 MAPK, p38 MAPK, and JNK activation is involved in LPS tolerance. Because NF-{kappa}B is a predominant signal transduction pathway involved in the activation of a wide variety of inflammatory genes, including the CAMs (25), and the inhibition of NF-{kappa}B translocation after repeated LPS stimulation has been considered as one potential mechanism of LPS tolerance in monocytes and macrophages (26), we specifically examined NF-{kappa}B activation in HIMEC. NF-{kappa}B translocation was inhibited by early (6-h) LPS pretreatment, but was not diminished at longer time periods (LPS pretreatment for 24 or 48 h). Because decreased mRNA and/or protein (E-selectin, IL-6, CD86) as well as decreased leukocyte binding were found in the LPS-pretreated HIMEC at distant time periods (24–48 h), we focused on additional signaling pathways that might mediate LPS-induced activation. Activation of MAPK family members is also integrally linked to inflammatory activation in endothelial cells, including HIMEC (13); thus, we also examined MAPK activation after repeated LPS stimulation, and found that p44/42 MAPK, p38 MAPK, and JNK phosphorylation by LPS stimulation were all inhibited by LPS pretreatment. Additionally, we demonstrated that p44/42 MAPK, p38 MAPK, or JNK activation is important for increased leukocyte adhesion and/or IL-6 secretion in HIMEC. These results indicate that the inhibitory effect of LPS pretreatment on MAPK activation may play a mechanistic role in the altered adhesion and protein expression that follow repeated LPS stimulation.

One striking finding in our study was the markedly enhanced Mn-SOD expression in HIMEC exposed to repeated LPS stimulation, which correlated with significant reduction in superoxide anion generation during HIMEC activation. Mn-SOD is a component of the cellular antioxidant defense and catalyzes the conversion of superoxide to hydrogen peroxide, which can be subsequently eliminated either by catalase or glutathione peroxide (27). Several reports have indicated that superoxide radicals increase leukocyte-endothelial cell adhesion, and SOD inhibits increased adhesion mediated by superoxide. In rat mesenteric microvessels, exogenous SOD inhibits leukocyte rolling, adhesion, and emigration induced by angiotensin II (28). In vitro, the adhesion of neutrophils to endothelial cells is increased by hydroxyradicals, and this enhanced PMN adhesion is blocked by SOD/catalase (29). Another report has demonstrated that the LPS-induced increase in leukocyte-endothelial adhesion in feline mesenteric vessels will be blocked by administration of SOD, indicating that the leukocyte adhesion induced by LPS is in part dependent on superoxide (30). These reports demonstrate that superoxide and the antioxidant defense system are important mediators of endothelial activation and enhanced endothelial-leukocyte adhesion following activation. In the present study, we demonstrate enhanced Mn-SOD expression and decreased superoxide in HIMEC repeatedly stimulated with LPS and have correlated this with diminished leukocyte adhesion. Enhanced Mn-SOD may represent an important mechanism that limits HIMEC intracellular superxoide anion, and may underlie decreased leukocyte adhesion in the setting of repeat LPS activation. Finally, the increased Mn-SOD expression in LPS-tolerant HIMEC is further proof that specific, regulated mechanisms involving increased expression of homeostatic genes as well as decreased expression of molecules involved in inflammatory activation are a component of endotoxin tolerance in HIMEC. Our findings are also the first description of decreased intracellular oxyradical stress occurring within the phenomenon of endotoxin tolerance in endothelial cells.

We have demonstrated that TLR4 mRNA and protein expression were not significantly altered by LPS treatment at the mRNA and protein levels. Although it is unknown whether endotoxin-tolerant human monocytes have a down-regulated expression of TLR4, reduced TLR4 mRNA and surface expression after LPS exposure have been reported in murine macrophages and are considered one of the potential mechanisms underlying impaired NF-{kappa}B activation in LPS-tolerant cells (19). However, impaired NF-{kappa}B translocation by LPS pretreatment was also observed in TLR4-transfected overexpressing cells (31), suggesting that down-regulation of TLR4 is not a necessary event in impaired signal transduction in LPS-tolerant monocytes. In HIMEC, NF-{kappa}B translocation was impaired by LPS pretreatment for 6 h, but not at longer periods (i.e., 24 h), and TLR4 expression was not altered at either of these time points. These results indicate that the altered signaling pathways in repeat LPS-treated HIMEC are not mediated by modulated TLR4 expression or internalization. Finally, preliminary experiments have demonstrated no activation of HIMEC with mycobacterial AraLAM (generous gift of P. Brennan, Colorado State University, Fort Collins, CO), a known ligand of TLR2, which suggests that potential cross-activation of other Toll-like receptors in HIMEC due to our dosage of commercial LPS will not be responsible for the endotoxin tolerance demonstrated in these studies (data not shown).

In summary, we conclude that HIMEC acquire endotoxin tolerance toward repeated LPS stimulation, characterized by reduced leukocyte adhesion, selectively decreased or increased gene/protein expression, impaired NF-{kappa}B and MAPK activation, and decreased superoxide production. Microvascular endothelial cells, such as monocytes/macrophages, have precisely defined immunoregulatory responses to repeated LPS exposure. LPS tolerance in HIMEC may represent an important mechanism in controlling gut inflammation during intestinal immune homeostasis in health and disease.


    Footnotes
 
1 This work was supported by Crohn’s and Colitis Foundation of America (to D.G.B.), National Institutes of Health DK 2407 and DK 56234 (to D.G.B.), American Lung Foundation (to P.R.), and Digestive Disease Center, Medical College of Wisconsin (to P.R., M.F.O, and D.G.B.). Back

2 Address correspondence and reprint requests to Dr. David G. Binion, Division of Gastroenterology and Hepatology, Froedtert Memorial Lutheran Hospital, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226. E-mail address: dbinion{at}mcw.edu Back

3 Abbreviations used in this paper: CAM, cell adhesion molecule; HIMEC, human intestinal microvascular endothelial cell; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; Mn-SOD, manganese superoxide dismutase; TLR4, Toll-like receptor 4. Back

Received for publication January 13, 2003. Accepted for publication April 7, 2003.


    References
 Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Binion, D. G., G. A. West, K. Ina, N. P. Ziats, S. N. Emancipator, C. Fiocchi. 1997. Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. Gastroenterology 112:1895.[Medline]
  2. Aderem, A., R. J. Ulevitch. 2000. Toll-like receptors in the induction of the innate immune response. Nature 406:782.[Medline]
  3. Faure, E., O. Equils, P. A. Sieling, L. Thomas, F. X. Zhang, C. J. Kirschning, N. Polentarutti, M. Muzio, M. Arditi. 2000. Bacterial lipopolysaccharide activates NF-{kappa}B through Toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells: differential expression of TLR-4 and TLR-2 in endothelial cells. J. Biol. Chem. 275:11058.[Abstract/Free Full Text]
  4. Zeuke, S., A. J. Ulmer, S. Kusumoto, H. A. Katus, H. Heine. 2002. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovasc. Res. 56:126.[Abstract/Free Full Text]
  5. Greer, G. G., E. T. Rietschel. 1978. Inverse relationship between the susceptibility of lipopolysaccharide (lipid A)-pretreated mice to the hypothermic and lethal effect of lipopolysaccharide. Infect. Immun. 20:366.[Abstract/Free Full Text]
  6. Munoz, C., J. Carlet, C. Fitting, B. Misset, J. P. Bleriot, J. M. Cavaillon. 1991. Dysregulation of in vitro cytokine production by monocytes during sepsis. J. Clin. Invest. 88:1747.
  7. Yoza, B. K., J. Y. Hu, S. L. Cousart, C. E. McCall. 2000. Endotoxin inducible transcription is repressed in endotoxin tolerant cells. Shock 13:236.[Medline]
  8. Randow, F., U. Syrbe, C. Meisel, D. Krausch, H. Zuckermann, C. Platzer, H. D. Volk. 1995. Mechanism of endotoxin desensitization: involvement of interleukin 10 and transforming growth factor {beta}. J. Exp. Med. 181:1887.[Abstract/Free Full Text]
  9. LaRue, K. E., C. E. McCall. 1994. A labile transcriptional repressor modulates endotoxin tolerance. J. Exp. Med. 180:2269.[Abstract/Free Full Text]
  10. West, M. A., W. Heagy. 2002. Endotoxin tolerance: a review. Crit. Care Med. 30:S64.[Medline]
  11. Lawrence, M. B., L. V. McIntire, S. G. Eskin. 1987. Effect of flow on polymorphonuclear leukocyte/endothelial cell adhesion. Blood 70:1284.[Abstract/Free Full Text]
  12. Peiper, S. C., Z. X. Wang, K. Neote, A. W. Martin, H. J. Showell, M. J. Conklyn, K. Ogborne, T. J. Hadley, Z. H. Lu, J. Hesselgesser, et al 1995. The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. J. Exp. Med. 181:1311.[Abstract/Free Full Text]
  13. Rafiee, P., C. P. Johnson, M. S. Li, H. Ogawa, J. Heidemann, P. J. Fisher, T. H. Lamirand, M. F. Otterson, K. T. Wilson, D. G. Binion. 2002. Cyclosporine A enhances leukocyte binding by human intestinal microvascular endothelial cells through inhibition of p38 MAPK and iNOS: paradoxical pro-inflammatory effect on the microvascular endothelium. J. Biol. Chem. 10:10.
  14. Griendling, K. K., D. Sorescu, B. Lassegue, M. Ushio-Fukai. 2000. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler. Thromb. Vasc. Biol. 20:2175.[Abstract/Free Full Text]
  15. Haraldsen, G., L. M. Sollid, O. Bakke, I. N. Farstad, D. Kvale, D. Molberg, J. Norstein, E. Stang, P. Brandtzaeg. 1998. Major histocompatibility complex class II-dependent antigen presentation by human intestinal endothelial cells. Gastroenterology 114:649.[Medline]
  16. Rafiee, P., P. J. Fisher, D. J. Stein, C. P. Johnson, D. G. Binion. 1999. ICAM-1, but not VCAM-1, expression is blocked with tyrosine phosphorylation inhibitors in activated human intestinal microvascular endothelial cells (HIMEC): potential role of ERK and P38 MAPK. Gastroenterology 116:G4002.
  17. Li, M. S., P. Rafiee, P. J. Fisher, T. H. Lamiland, A. R. Taras, V. B. Shidham, C. P. Johnson, D. G. Binion. 2000. Vascular cell adheison molecule-1 (VCAM-1) expression in human intestinal microvascular endothelial cells (HIMEC) is mediated by JNK, intracellular oxyradicals and NF{kappa}B activation. Gastroenterology 118:3153.
  18. Jersmann, H. P. A., C. S. T. Hii, J. V. Ferrante, A. Ferrante. 2001. Bacterial lipopolysaccharide and tumor necrosis factor {alpha} synergistically increase expression of human endothelia adhesion molecules through activation of NF-{kappa}B and p38 mitogen-activated protein kinase signaling pathways. Infect. Immun. 69:1273.[Abstract/Free Full Text]
  19. Nomura, F., S. Akashi, Y. Sakao, S. Sato, T. Kawai, M. Matsumoto, K. Nakanishi, M. Kimoto, K. Miyake, K. Takeda, S. Akira. 2000. Cutting edge: endotoxin tolerance in mouse peritoneal macrophages correlates with down-regulation of surface Toll-like receptor 4 expression. J. Immunol. 164:3476.[Abstract/Free Full Text]
  20. Calandra, T.. 2001. Pathogenesis of septic shock: implications for prevention and treatment. J. Chemother. 13:173.
  21. Sartor, R. B.. 1997. Pathogenesis and immune mechanisms of chronic inflammatory bowel disease. Am. J. Gastroenterol. 92:5.S.[Medline]
  22. Wolk, K., W. D. Docke, V. von Baehr, H. D. Volk, R. Sabat. 2000. Impaired antigen presentation by human monocytes during endotoxin tolerance. Blood 96:218.[Abstract/Free Full Text]
  23. Lush, C. W., G. Cepinskas, P. R. Kvietys. 2000. LPS tolerance in human endothelial cells: reduced PMN adhesion, E- selectin expression, and NF-{kappa}B mobilization. Am. J. Physiol. Heart Circ. Physiol. 278:H853.[Abstract/Free Full Text]
  24. Bauer, P., T. Welbourne, T. Shigematsu, J. Russell, D. N. Granger. 2000. Endothelial expression of selectins during endotoxin preconditioning. Am. J. Physiol. Regul. Integr. Comp. Physiol. 279:R2015.[Abstract/Free Full Text]
  25. Collins, T., M. A. Read, A. S. Neish, M. Z. Whitley, D. Thanos, T. Maniatis. 1995. Transcriptional regulation of endothelial cell adhesion molecules: NF-{kappa}B and cytokine-inducible enhancers. FASEB J. 9:899.[Abstract]
  26. Medvedev, A. E., K. M. Kopydlowski, S. N. Vogel. 2000. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and Toll-like receptor 2 and 4 gene expression. J. Immunol. 164:5564.[Abstract/Free Full Text]
  27. Halliwell, B., J. M. C. Gutteridge. 1999. Free Radicals in Biology and Medicine Oxford University Press, New York..
  28. Alvarez, A., M. J. Sanz. 2001. Reactive oxygen species mediate angiotensin II-induced leukocyte-endothelial cell interactions in vivo. J. Leukocyte Biol. 70:199.[Abstract/Free Full Text]
  29. Suzuki, K., H. Eguchi, Y. H. Koh, Y. S. Park, N. Taniguchi. 1999. Acceleration of adhesion of cancer cells and neutrophils to endothelial cells in the absence of de novo protein synthesis: possible implication for involvement of hydroxyl radicals. Biochem. Biophys. Res. Commun. 257:214.[Medline]
  30. Harris, N. R., J. M. Russell, D. N. Granger. 1994. Mediators of endotoxin-induced leukocyte adhesion in mesenteric postcapillary venules. Circ. Shock 43:155.[Medline]
  31. Medvedev, A. E., P. Henneke, A. Schromm, E. Lien, R. Ingalls, M. J. Fenton, D. T. Golenbock, S. N. Vogel. 2001. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J. Immunol. 167:2257.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
J. Immunol.Home page
B. Lozanoska-Ochser, N. J. Klein, G. C. Huang, R. A. Alvarez, and M. Peakman
Expression of CD86 on Human Islet Endothelial Cells Facilitates T Cell Adhesion and Migration
J. Immunol., November 1, 2008; 181(9): 6109 - 6116.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
L. Deban, C. Correale, S. Vetrano, A. Malesci, and S. Danese
Multiple Pathogenic Roles of Microvasculature in Inflammatory Bowel Disease: A Jack of All Trades
Am. J. Pathol., June 1, 2008; 172(6): 1457 - 1466.
[Abstract] [Full Text] [PDF]


Home page
J. Histochem. Cytochem.Home page
Y. Sawa, T. Ueki, M. Hata, K. Iwasawa, E. Tsuruga, H. Kojima, H. Ishikawa, and S. Yoshida
LPS-induced IL-6, IL-8, VCAM-1, and ICAM-1 Expression in Human Lymphatic Endothelium
J. Histochem. Cytochem., February 1, 2008; 56(2): 97 - 109.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
M. Muthukuru and C. W. Cutler
Antigen Capture of Porphyromonas gingivalis by Human Macrophages Is Enhanced but Killing and Antigen Presentation Are Reduced by Endotoxin Tolerance
Infect. Immun., February 1, 2008; 76(2): 477 - 485.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
J. Heidemann, C. Ruther, M. Kebschull, W. Domschke, M. Bruwer, S. Koch, T. Kucharzik, and C. Maaser
Expression of IL-12-related molecules in human intestinal microvascular endothelial cells is regulated by TLR3
Am J Physiol Gastrointest Liver Physiol, December 1, 2007; 293(6): G1315 - G1324.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. E. Medvedev, W. Piao, J. Shoenfelt, S. H. Rhee, H. Chen, S. Basu, L. M. Wahl, M. J. Fenton, and S. N. Vogel
Role of TLR4 Tyrosine Phosphorylation in Signal Transduction and Endotoxin Tolerance
J. Biol. Chem., June 1, 2007; 282(22): 16042 - 16053.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Danese, E. Dejana, and C. Fiocchi
Immune Regulation by Microvascular Endothelial Cells: Directing Innate and Adaptive Immunity, Coagulation, and Inflammation
J. Immunol., May 15, 2007; 178(10): 6017 - 6022.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
P. Brun, I. Castagliuolo, V. D. Leo, A. Buda, M. Pinzani, G. Palu, and D. Martines
Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis
Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G518 - G525.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
J. Heidemann, W. Domschke, T. Kucharzik, and C. Maaser
Intestinal microvascular endothelium and innate immunity in inflammatory bowel disease: a second line of defense?
Infect. Immun., October 1, 2006; 74(10): 5425 - 5432.
[Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
M. Fukata, K. S. Michelsen, R. Eri, L. S. Thomas, B. Hu, K. Lukasek, C. C. Nast, J. Lechago, R. Xu, Y. Naiki, et al.
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis
Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G1055 - G1065.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. T. Abreu, M. Fukata, and M. Arditi
TLR Signaling in the Gut in Health and Disease
J. Immunol., April 15, 2005; 174(8): 4453 - 4460.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
J. Li, Z. Ma, Z.-L. Tang, T. Stevens, B. Pitt, and S. Li
CpG DNA-mediated immune response in pulmonary endothelial cells
Am J Physiol Lung Cell Mol Physiol, September 1, 2004; 287(3): L552 - L558.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
C. Maaser, J. Heidemann, C. von Eiff, A. Lugering, T. W. Spahn, D. G. Binion, W. Domschke, N. Lugering, and T. Kucharzik
Human Intestinal Microvascular Endothelial Cells Express Toll-Like Receptor 5: A Binding Partner for Bacterial Flagellin
J. Immunol., April 15, 2004; 172(8): 5056 - 5062.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ogawa, H.
Right arrow Articles by Binion, D. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ogawa, H.
Right arrow Articles by Binion, D. G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS